eClinical Technology and Industy News

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease

Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN, a key regulator of immune activity and lysosomal function in the brain

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, reported safety and biomarker data from a first-in-human Phase 1 healthy volunteer study of AL101, a human monoclonal antibody that blocks the sortilin receptor to increase progranulin levels. The data will be presented today during a poster session at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco from November 29–December 2, 2022. AL101 is being developed for the potential treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), under Alector’s collaboration with GSK.

In a randomized, double-blind, placebo-controlled Phase 1 study in 88 heathy volunteers who received either single or multiple doses of AL101 administered intravenously (IV) or subcutaneously (SC), AL101 was generally well tolerated and elevated PGRN levels in the cerebrospinal fluid (CSF). The study results that will be presented today from the multiple-dose (MD) cohorts demonstrated that the product candidate’s pharmacokinetic (PK) and pharmacodynamic (PD) profile supports development in multiple dosing schedules for chronic neurodegenerative conditions, such as AD and PD.

“Phase 1 study results demonstrated that AL101 elevated progranulin levels, and these results pave the way for exploring multiple indications and dosing schedules for AL101,” said Gary Romano, M.D., Ph.D., Chief Medical Officer of Alector.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?